Clinical trial

RElugolix VErsus LeUprolide Cardiac Trial

NCT05320406

StatusACTIVE_NOT_RECRUITING

Study typeINTERVENTIONAL

Start date2022-06-06

PhasePHASE2

Study timeline

Study start (actual)2022-06-06Date precision: day

Registry last updated2026-02-12

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Biochemically Recurrent Prostate Carcinomaunresolved

Localized Prostate Carcinomaunresolved

Stage I Prostate Cancer AJCC v8unresolved

Stage II Prostate Cancer AJCC v8unresolved

Stage IIA Prostate Cancer AJCC v8unresolved

Stage IIB Prostate Cancer AJCC v8unresolved

Stage IIC Prostate Cancer AJCC v8unresolved

Stage III Prostate Cancer AJCC v8unresolved

Stage IIIA Prostate Cancer AJCC v8unresolved

Stage IIIB Prostate Cancer AJCC v8unresolved

Stage IIIC Prostate Cancer AJCC v8unresolved

Interventions

Radiation therapyRADIATION

LeuprolideDRUG · verified · RxNorm: leuprolide

RelugolixDRUG · verified · RxNorm: relugolix

Sponsors & collaborators

Emory Universitylead sponsor

National Cancer Institute (NCI)collaborator

Prostate Cancer Foundationcollaborator

Mapped research locations

AtlantaGeorgia, United States4

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT05320406 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.